Arrowhead Pharmaceuticals Inc

9 de out. de 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

8 de out. de 2026, 20:07 UTC

Arrowhead Pharmaceuticals announces FDA entry of plozasiran into the Split Real Time Application Review pilot program, despite ongoing declines in its stock price.

6 de out. de 2026, 20:00 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, trading at 62, marking the fifth consecutive session of lower closes and remaining significantly below its 20-day moving average.

5 de out. de 2026, 21:20 UTC

Arrowhead Pharmaceuticals Inc shares are advancing in after-market trading, recovering from an earlier dip to reach their highest point of the day amid increased social media attention.

3 de out. de 2026, 00:00 UTC

Arrowhead Pharmaceuticals Inc has advanced in after-market trading, recovering from an initial dip and marking a notable recovery since Friday's close.

2 de out. de 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell modestly, continuing a downward trend with three consecutive sessions finishing lower amid a broader market decline.

1 de out. de 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, continuing a decline since Wednesday's close and remaining well below the 20-day moving average.

30 de set. de 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply as the company announced an R&D webinar on ARO-MAPT, closing near the lower end of its one-month range.

29 de set. de 2026, 21:20 UTC

Arrowhead Pharmaceuticals Inc. has announced a research and development webinar on ARO-MAPT, with the stock moving higher in after-market trading.

28 de set. de 2026, 19:55 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions of losses and trading below the 20-day moving average.

26 de set. de 2026, 00:01 UTC

Arrowhead Pharmaceuticals Inc is trading modestly lower in after-market hours, marking its lowest cumulative return since Friday and extending five consecutive sessions of declines.

24 de set. de 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a price target of $74 amid mixed fiscal results.

23 de set. de 2026, 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

22 de set. de 2026, 20:06 UTC

Arrowhead Pharmaceuticals Inc is higher in Tuesday's trading, having gained notably from Monday's close, despite pulling back from a mid-afternoon peak.

21 de set. de 2026, 23:25 UTC

Arrowhead Pharmaceuticals Inc declined in after-market trading, moving lower from Monday's close and remaining near the lower end of its one-month trading range.

18 de set. de 2026, 23:12 UTC

Arrowhead Pharmaceuticals Inc is experiencing notable strength in after-market trading, rising sharply despite initial sales figures for TRYNGOLZA being deemed unreliable by Ionis' CEO.

17 de set. de 2026, 22:56 UTC

Arrowhead Pharmaceuticals Inc is trading roughly flat in after-market hours, maintaining little change since Thursday's close amid a notable decline over the past month.

16 de set. de 2026, 22:31 UTC

Arrowhead Pharmaceuticals Inc is rising in after-market trading, rebounding sharply amid retail commentary on its resilience despite challenges in the biotechnology sector.

15 de set. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals is gaining in after-market hours following positive interim data from its ARO-DIMER-PA trial, amid a broader market uptrend.

14 de set. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower amid broader market pressures, driven by renewed inflation concerns and supply chain disruptions.

11 de set. de 2026, 23:26 UTC

Arrowhead Pharmaceuticals shares rose in after-market trading, amid steady U.S. inflation data and speculation about potential Federal Reserve interest rate hikes.

10 de set. de 2026, 19:56 UTC

Arrowhead Pharmaceuticals shares are higher during Thursday's session, despite fluctuations and remaining below the 20-day moving average amid broader market trends.

9 de set. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals is lower today despite Citi initiating coverage with a "Buy" rating and a price target of $108. The stock has declined for four sessions.

8 de set. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading lower today, following Citi's initiation of coverage with a Buy rating and a $108 price target.

4 de set. de 2026, 23:10 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours following Friday's close. Broader market caution amid mixed economic signals may be influencing this movement.

3 de set. de 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares are higher as the company announces participation in several upcoming investor conferences, enhancing visibility among investors and analysts.

2 de set. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, reflecting a notable decline since Wednesday's close amid broader market tensions and rising oil prices.

1 de set. de 2026, 19:46 UTC

HC Wainwright reiterated its Buy rating on Arrowhead Pharmaceuticals, maintaining a $120 price target as shares advance during the session.

31 de ago. de 2026, 20:01 UTC

Arrowhead Pharmaceuticals shares are lower despite promising Phase 3 results for plozasiran, which showed significant triglyceride reductions in patients.

28 de ago. de 2026, 21:01 UTC

Arrowhead Pharmaceuticals Inc. shares are higher in after-market trading, continuing a modest rise since Friday's close, despite remaining below the 20-day moving average.